Hey guys
Found this article published 2 September (most recent)
https://academic.oup.com/braincomms/article/3/3/fcab202/6362870
Worth a read
Note this under competing interests
Grech consultancy works for Invex therapeutics (2020). S.P.M. has received Honoria from Novartis for speaking on topics unrelated to this drug, but within a national headache network meeting (November 2019) and consultancy work for Invex therapeutics (2020). A.J.S. has received speaker fees and honoraria from Novartis and Allergan, but not related to IIH, also Invex therapeutics company director with salary and stock options (2019, 2020)
Ann: Appendix 4E and Annual Report, page-35
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125000 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.8¢ | 5755 | 1 |
View Market Depth
| Last trade - 16.12pm 15/10/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable